Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026)
Ardelyx's (ARDX) quarterly Non-Current Deffered Revenue came in at $13.7 million in Q1 2026, up 64.06% YoY from $8.4 million in Q1 2025, and little changed on a QoQ basis from $13.7 million in Q4 2025.
Ardelyx (ARDX) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 9 years of Non-Current Deffered Revenue data on file, last reported at $13.7 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 64.06% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (up 64.06% YoY) and the FY2025 annual result came in at $13.7 million, up 89.42% from the prior year.
- Non-Current Deffered Revenue steadied at $13.7 million in Q1 2026, from $13.7 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $13.7 million in Q3 2025 to a low of $7.2 million in Q4 2024.
- A 5-year average of $10.7 million and a median of $10.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 321.48% — and 2025, when it sank 31.01%.
- Tracing ARDX's Non-Current Deffered Revenue over 5 years: stood at $9.0 million in 2022, then declined by 4.22% to $8.6 million in 2023, then dropped by 16.34% to $7.2 million in 2024, then soared by 89.42% to $13.7 million in 2025, then changed by 0.0% to $13.7 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $13.7 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.70 Mn |
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 13.70 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 12.77 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Dec 31, 2023 | 8.64 Mn |
| Sep 30, 2023 | 10.29 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 11.50 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 8.56 Mn |
| Jun 30, 2022 | 12.42 Mn |
| Mar 31, 2022 | 8.56 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Sep 30, 2021 | 2.95 Mn |